Use of fibroscan assessment to determine MASLD in a diverse paediatric obesity cohort
Bolton O, Peh G, Shah P, P DA, Salam Z, Xu R, Scroth J, M HS et al.
Endocrine Abstracts, Bioscientifica 
13-02-2026

Cardiovascular Risk in MASLD: What Multiple Lines of Evidence Reveal
Sattar N, Dalakoti M, Alazawi W, Aroda VR
Journal of Hepatology, Elsevier 
01-02-2026

Liver Stiffness Rises Early in MASLD and Drives Inflammation, Lipid Dysmetabolism, and Fibrosis via Piezo1–YAP Mechanotransduction
Ma J, Xie N, Wang Z, Liang X, Han Y, Zhao Q, Wang M, Lu H et al.
Advanced Science, Wiley vol. 13 (19) 
04-01-2026

Doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis—leave no one behind: author's reply
Lazarus JV, Alazawi W, Byrne CD, Caussy C, Brennan PN
The Lancet Regional Health - Europe, Elsevier vol. 60 
26-12-2025

Diagnostic Performance of LIVERFASt as a Non-invasive Liver Fibrosis Test: Data from Three Cohorts of Patients with Metabolic Dysfunction-associated Steatotic Liver Disease.
Alkhouri N, Mantry P, Gonzalez HC, Patil R, McIntyre V, Kohli A, Rudraraju M, Kosinski JF et al.
Journal of Gastrointestinal and Liver Diseases, Romanian Society of Gastroenterology and Hepatology vol. 34 (4), 437-450.  
26-12-2025

Real-world evidence in metabolic dysfunction-associated steatotic liver disease (MASLD): insights, challenges, and future directions
Huang H-T, Hewitt M, Li W, Alazawi W
The Lancet Regional Health - Europe, Elsevier vol. 62 
13-12-2025

Nutrition in MASLD: a patient focused, evidence-based clinician’s guide
Pekarska K, Brennan PN, Wajcman DI, Towey J, Cox L, Weatherby K, McPherson S, Stine J et al.
Frontline Gastroenterology, Bmj vol. 17 (3) 
30-11-2025

Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis
Li W, Alazawi W, Loomba R
The Lancet Gastroenterology & Hepatology, Elsevier vol. 11 (2), 150-162.  
27-11-2025

Metabolic dysfunction-associated steatotic liver disease
Hsu C, Alazawi W
Clinical Medicine, Elsevier vol. 25 (6) 
25-10-2025

P69 Tapping into trouble: delays in diagnostic paracentesis in decompensated cirrhosis
Miller H, Temperley L, Khanna K, Phillips A, Patel K, Wells G, Hearn T, Diver W et al.
P69 Tapping into trouble: delays in diagnostic paracentesis in decompensated cirrhosis. 
01-10-2025

P13 Baseline characteristics in well-compensated NASH cirrhosis patients diagnosed with or without a liver biopsy in MAESTRO-NASH-OUTCOMES, a clinical outcome Phase 3 study assessing the effect of resmetirom in well compensated NASH cirrhosis
Alazawi W
P13 Baseline characteristics in well-compensated NASH cirrhosis patients diagnosed with or without a liver biopsy in MAESTRO-NASH-OUTCOMES, a clinical outcome Phase 3 study assessing the effect of resmetirom in well compensated NASH cirrhosis. 
01-10-2025

P11 Dietary patterns, physical activity levels and mental health status of patients with metabolic dysfunction-associated steatotic liver disease living in East London
Cox L, Imran H, Lim TY, Brindley JH, Muchelemba E, Alazawi W, Sharma V
P11 Dietary patterns, physical activity levels and mental health status of patients with metabolic dysfunction-associated steatotic liver disease living in East London. 
01-10-2025

P5 Pegozafermin treatment demonstrates long-term benefit in subjects with metabolic dysfunction-associated steatohepatitis and fibrosis: results from the Phase 2b ENLIVEN clinical trial
Alazawi W, Sanyal AJ, Schattenberg J, Feng S, Gottwald MD, Mansbach H, Margalit M, Hartsfield C et al.
P5 Pegozafermin treatment demonstrates long-term benefit in subjects with metabolic dysfunction-associated steatohepatitis and fibrosis: results from the Phase 2b ENLIVEN clinical trial. 
01-10-2025

P91 Multidisciplinary one-stop diagnostic liver clinic delivers 46% discharge rate at first appointment
Kerry G, Brindley JH, Lim TY, Cox L, Muchelemba E, Sharma V, Alazawi W
P91 Multidisciplinary one-stop diagnostic liver clinic delivers 46% discharge rate at first appointment. 
01-10-2025

Epidemiology of Metabolic Dysfunction–Associated Steatotic Liver Disease in South Asian Ethnicities: A Systematic Review and Meta‐Analysis
James M, Smuk M, Rahman N, Black G, Alazawi W
Journal of Gastroenterology and Hepatology, Wiley vol. 40 (12), 2830-2841.  
26-09-2025

The People-First Liver Charter
Lazarus JV, Ivancovsky Wajcman D, Pannain S, Brennan PN, Manolas MI, Jepsen P, Treloar C, Arora AK et al.
Nature Medicine, Springer Nature vol. 31 (7), 2109-2116.  
05-06-2025

A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis
Lazarus JV, Brennan PN, Mark HE, Alazawi W, Allen AM, Byrne CD, Castera L, Caussy C et al.
The Lancet Regional Health - Europe, Elsevier vol. 54 
04-06-2025

FP13 The urine steroid metabolome combined with machine learning performs similarly to established non-invasive markers to identify advanced MASLD fibrosis
Miller H, Brandhof EVD, Simpson J, Denham S, Harman D, Aithal GP, Manousou P, Cobbold J et al.
Flash Presentations. 
01-06-2025

High inherited risk predicts age-associated increases in fibrosis in patients with MASLD
Díaz LA, Alazawi W, Agrawal S, Arab JP, Arrese M, Idalsoaga F, Barreyro FJ, Gadano A et al.
Journal of Hepatology, Elsevier vol. 83 (4), 849-859.  
05-05-2025

TOP-441 CD8+ T cells are pro-inflammatory, cytotoxic, and clonally expanded in the early stages of fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH)
Kumar R, Li W, Loy J, Devalia K, Goralcyzk A, Malik H, James L, Marelli-Berg F et al.
Journal of Hepatology, Elsevier vol. 82 
01-05-2025

WED-419 The urine steroid metabolome combined with machine learning performs similarly to established non-invasive markers to risk stratify for the presence of advanced MASLD fibrosis
Miller H, van den Brandhof E, Simpson J, Denham S, Harman D, Aithal G, Manousou P, Cobbold J et al.
Journal of Hepatology, Elsevier vol. 82, s550-s551.  
01-05-2025

THU-025-YI Prevalence of and outcomes related to metabolic dysfunction-associated steatotic liver disease (MASLD) in a nationwide cohort: insights from over 23 million individuals in Taiwan’s national health insurance research database
Huang H-T, Lin L-Y, Lee C-P, Hewitt M, Chaplin C, Yang Y-H, Alazawi W
Journal of Hepatology, Elsevier vol. 82 
01-05-2025

An Expert Consensus Delphi Panel in Metabolic Dysfunction- and Alcohol-associated Liver Disease: Opportunities and Challenges in Clinical Practice
Diaz LA, Ajmera V, Arab JP, Huang DQ, Hsu C, Lee BP, Louvet A, Thiele M et al.
Clinical Gastroenterology and Hepatology, Elsevier vol. 24 (3), 633-645.e4.  
30-04-2025

Current Surveillance Strategy Is Less Effective for Detecting Early-Stage Hepatocellular Carcinoma in Patients with Non-Viral and Non-Cirrhotic Liver Disease
Spiers J, Li W, Aravinthan AD, Bannaga A, Caddick K, Culver EL, Faulkes RE, Gordon V et al.
Liver Cancer, Karger Publishers vol. 14 (5), 587-600.  
26-03-2025

A European Survey to Identify Challenges in the Management of Metabolic Dysfunction‐Associated Steatotic Liver Disease
Castera L, Alazawi W, Bugianesi E, Caussy C, Federici M, Schattenberg JM, Basuroy R
Liver International, Wiley vol. 45 (2) 
03-01-2025

Metabolic dysfunction over a life course key to healthy ageing inequality
Littlewood K, Gegic J, Hickman M, Henson RCJ, Bishop JR, Kershaw T, Diamond P, Slabaugh G et al.
Aging Clinical and Experimental Research, Springer Nature vol. 37 (1) 
01-01-2025

Endogenous C-type natriuretic peptide offsets the pathogenesis of steatohepatitis, hepatic fibrosis, and portal hypertension
Perez-Ternero C, Li W, Aubdool AA, Goldin RD, Loy J, Devalia K, Alazawi W, Hobbs AJ
Pnas Nexus, Oxford University Press (Oup) vol. 4 (1) 
23-12-2024

A social media listening study of patients’ experiences relating to metabolic dysfunction-associated steatotic liver disease: The LISTEN-MASLD study
Lazarus JV, Alazawi W, Basuroy R, Castera L, Koulla Y, Prasad P, Romero-Gomez M
Annals of Hepatology, Elsevier vol. 30 (1) 
02-12-2024

Glycated haemoglobin is a major predictor of disease severity in patients with NAFLD
Colosimo S, Miller H, Koutoukidis DA, Marjot T, Tan GD, Harman DJ, Aithal GP, Manousou P et al.
Diabetes Research and Clinical Practice, Elsevier vol. 217 
13-08-2024

Update on Treatment for Metabolic Dysfunction-Associated Steatohepatitis Cirrhosis.
Alazawi W
Gastroenterology & Hepatology vol. 20 (4), 241-243.  
01-04-2024

Progress is impossible without change: understanding the evolving nomenclature of steatotic liver disease and its effect on hepatology practice
Brennan PN, Tavabie OD, Li W, Marjot T, Corless L, Fallowfield JA, Jarvis H, Mansour D et al.
The Lancet Gastroenterology & Hepatology, Elsevier vol. 9 (6), 577-582.  
28-02-2024

Translating the potential of the urine steroid metabolome to stage NAFLD (TrUSt-NAFLD): study protocol for a multicentre, prospective validation study
Miller H, Harman D, Aithal GP, Manousou P, Cobbold JF, Parker R, Sheridan D, Newsome PN et al.
Bmj Open, Bmj vol. 14 (1) 
01-01-2024

The role of glycated haemoglobin in predicting disease severity in non-alcoholic fatty liver disease
Colosimo S, Miller H, Koutoukidis D, Marjot T, Harman D, Aithal G, Manousou P, Forlano R et al.
Endocrine Abstracts, Bioscientifica 
31-10-2023

Non-invasive Tests of Fibrosis: Does One Size Fit All?
James M, Alazawi W
Digestive Diseases and Sciences, Springer Nature vol. 68 (12), 4285-4286.  
04-10-2023

Automated and reproducible cell identification in mass cytometry using neural networks
Saihi H, Bessant C
Briefings in Bioinformatics, Oxford University Press (Oup) vol. 24 (6) 
22-09-2023

National study of NAFLD management identifies variation in delivery of care in the UK between 2019 to 2022
Li W, Sheridan D, McPherson S, Alazawi W, Abeysekera K, Marjot T, Brennan P, Mahgoub S et al.
Jhep Reports, Elsevier vol. 5 (12) 
28-08-2023

A global action agenda for turning the tide on fatty liver disease
Lazarus JV, Mark HE, Allen AM, Arab JP, Carrieri P, Noureddin M, Alazawi W, Alkhouri N et al.
Hepatology, Wolters Kluwer vol. 79 (2), 502-523.  
04-08-2023

A global research priority agenda to advance public health responses to fatty liver disease
Lazarus JV, Mark HE, Allen AM, Arab JP, Carrieri P, Noureddin M, Alazawi W, Alkhouri N et al.
Journal of Hepatology, Elsevier vol. 79 (3), 618-634.  
20-06-2023

Measuring NAFLD models of care
Allen AM, Younossi ZM, Tsochatzis EA, Zelber-Sagi S, Cusi K
Nature Reviews Gastroenterology & Hepatology, Springer Nature vol. 20 (10), 626-627.  
08-06-2023

Feasibility and acceptability of a primary care liver fibrosis testing pathway centred on the diabetes annual review: PRELUDE1 prospective cohort study protocol
Brindley JH, Abeysekera K, Hood G, Jennings S, Moore J, Hickman M, Alazawi W
Bmj Open, Bmj vol. 13 (5) 
01-05-2023

Renal dysfunction in liver disease
Faloon S, Alazawi W
Medicine, Elsevier vol. 51 (J Hepatol 62 2015), 288-292.  
01-04-2023

Single-cell phenotypes of peripheral blood immune cells in early and late stages of non-alcoholic fatty liver disease
Waller KJ, Saihi H, Li W, Brindley JH, De Jong A, Syn W-K, Bessant C, Alazawi W
Clinical and Molecular Hepatology, The Korean Association For The Study of The Liver vol. 29 (2), 417-432.  
21-11-2022

Myeloid XBP1 links lipid overload with inflammation in NASH: Do advances in basic science have clinical potential?
Alazawi W
Journal of Hepatology, Elsevier vol. 77 (2), 290-292.  
11-06-2022

What’s new in non-alcoholic fatty liver disease?
Spiers J, Brindley JH, Li W, Alazawi W
Frontline Gastroenterology, Bmj vol. 13 (e1), e102-e108.  
31-05-2022

Association of gamma-glutamyltransferase levels with total mortality, liver-related and cardiovascular outcomes: A prospective cohort study in the UK Biobank
Ho FK, Ferguson LD, Gray SR, Forrest E, Gill JM, Katikireddi SV, Cleland JG, Pell JP
Eclinicalmedicine, Elsevier vol. 48 
12-05-2022

Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group
McPherson S, Armstrong MJ, Cobbold JF, Corless L, Anstee QM, Aspinall RJ, Barclay ST, Brennan PN et al.
The Lancet Gastroenterology & Hepatology, Elsevier vol. 7 (8), 755-769.  
28-04-2022

The contribution of daytime sleepiness to impaired quality of life in NAFLD in an ethnically diverse population
Li W, Kadler BK, Brindley JH, Hood G, Devalia K, Loy J, Syn W-K, Alazawi W
Scientific Reports, Springer Nature vol. 12 (1) 
24-03-2022

Identification of liver disease: why and how
Macpherson I, Abeysekera KWM, Harris R, Mansour D, McPherson S, Rowe I, Dillon JF
Frontline Gastroenterology, Bmj vol. 13 (5), 367-373.  
24-01-2022

The growing prevalence of nonalcoholic fatty liver disease (NAFLD), determined by fatty liver index, amongst young adults in the United States. A 20-year experience
Li W, Ng CH, Quek J, Chan KE, Tan C, Zeng RW, Yong JN, Tay H et al.
Metabolism and Target Organ Damage, Oae Publishing vol. 2 (4), null-null.  
01-01-2022

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. Reply.
Gordon AC, Angus DC, Derde LPG
New England Journal of Medicine vol. 385 (12), 1147-1149.  
18-08-2021

Undiagnosed obstructive sleep apnoea is a major component in NAFLD quality of life impairment
Li W, Kadler BK, Brindley JH, Berryman V, Preston J, Pattrick M, Sutcliffe C, Hood G et al.
 
01-01-2021

Non-alcoholic fatty liver disease
Li W, Alazawi W
Clinical Medicine, Elsevier vol. 20 (5), 509-512.  
01-09-2020

Socioeconomic Factors Associated With Liver-Related Mortality From 1985 to 2015 in 36 Developed Countries
Li W, Kemos P, Salciccioli JD, Marshall DC, Shalhoub J, Alazawi W
Clinical Gastroenterology and Hepatology, Elsevier vol. 19 (8), 1698-1707.e13.  
22-08-2020

THU047 Serious complications due to study-mandated liver biopsies in phase 3 trials for patients with advanced fibrosis due to non-alcoholic steatohepatitis
Anstee Q, Patel K, Laurent C, Shiffman M, M M, Chen C-Y, George Goh BB, Alazawi W et al.
Journal of Hepatology, Elsevier vol. 73 
01-08-2020

SAT022 Simultaneous intra-operative sampling from multiple anatomical sites reveals pro-inflammatory liver homing T cells in liver, adipose tissue and peripheral blood in patients with NASH
Brindley J, Tailor F, Waller K, Jong AV-D, Devalia K, Alazawi W
 
01-08-2020

FRI264 Improvements in the ELF test are associated with widespread changes in the hepatic transcriptome in patients with advanced fibrosis due to non-alcoholic steatohepatitis
Younossi ZM, Anstee Q, Harrison S, Trauner M, Lawitz E, Wong VW-S, Okanoue T, Gomez MR et al.
Journal of Hepatology, Elsevier vol. 73, s528-s530.  
01-08-2020

Stat2 loss disrupts damage signalling and is protective in acute pancreatitis
Heath H, Britton G, Kudo H, Renney G, Ward M, Hutchins R, Foster GR, Goldin RD et al.
The Journal of Pathology, Wiley vol. 252 (1), 41-52.  
23-07-2020

Improving prevention strategies for cardiometabolic disease
Sattar N, Alazawi W
Nature Medicine, Springer Nature vol. 26 (3), 320-325.  
01-03-2020

Genetics of Non-Alcoholic Fatty Liver and Cardiovascular Disease: Implications for Therapy?
Chandrasekharan K
Frontiers in Pharmacology, Frontiers vol. 10 
08-01-2020

Proteomic screening of plasma identifies potential noninvasive biomarkers associated with significant/advanced fibrosis in patients with nonalcoholic fatty liver disease
Hou W, Janech MG, Sobolesky PM, Bland AM, Samsuddin S
Bioscience Reports, Portland Press vol. 40 (1) 
03-01-2020

IMPACT ON INFLAMMATORY BIOMARKERS, LIPIDS, AND CARDIOVASCULAR SAFETY OF CENICRIVIROC WITH OR WITHOUT STATINS IN SUBJECTS WITH NASH AND SIGNIFICANT LIVER FIBROSIS: CENTAUR STUDY
Kowdley KV, Alazawi W, Lanthier N, Iacob A, Torstenson R, Seyedkazemi S
 
01-01-2020

Nonalcoholic Fatty Liver Disease
Alazawi W
In Liver Immunology, Springer Nature 325-334.  
01-01-2020

Obesity Predicts Liver Function Testing and Abnormal Liver Results
Li W, Homer K, Hull S, Boomla K, Robson J, Alazawi W
Obesity, Wiley vol. 28 (1), 132-138.  
05-12-2019

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A et al.
The Lancet, Elsevier vol. 394 (10215), 2184-2196.  
01-12-2019

Authors’ reply to McKenna-Barry and Ryan
Sattar N
The Bmj, Bmj vol. 367 
22-11-2019

Non‐alcoholic fatty liver disease in men
Michael E, Alazawi W
Trends in Urology & Men's Health, Wiley vol. 10 (6), 6-9.  
01-11-2019

Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults
Alexander M, Loomis AK, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, Lapi F, Rijnbeek P et al.
The Bmj, Bmj vol. 367 
08-10-2019

Renal dysfunction in liver disease
Michael E, Nadarajah L, Alazawi W
Medicine, Elsevier vol. 47 (Hepatol [Internet] 3), 679-683.  
01-10-2019

Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts
Alexander M, Loomis AK, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, Pasqua A, Lapi F et al.
Bmc Medicine, Springer Nature vol. 17 (1) 
20-05-2019

FRI-356-Single cell peripheral innate and adaptive immune signature of non-alcoholic steatohepatitis by cytometry time of flight
Waller K, Jong AV-D, Li W, Lowe R, Kemos P, Syn W-K, Alazawi W
 
01-04-2019

FRI-279-Stat2 is a pathogenic factor in human non-alcoholic steatohepatitis and mouse models of liver injury and mediates fatty acid-induced Inflammasome activation in hepatocytes
Li W, Britton G, Kudo H, Goldin RD, Alazawi W
 
01-04-2019

THU-315-Non-cirrhotic patients with non-alcoholic fatty liver disease have impaired quality of life: Independently predicted by body mass index, diabetes and liver stiffness
Kadler B, Brindley JH, Berryman V, Preston J, Syn W-K
 
01-04-2019

Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials
Nunez DJ, Alexander M, Yerges-Armstrong L, Singh G, Byttebier G, Fabbrini E, Waterworth D, Wallentin L et al.
Ajp Gastrointestinal and Liver Physiology, American Physiological Society vol. 316 (3), g372-g386.  
29-11-2018

Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease
Alexander M, Loomis AK, Fairburn-Beech J, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, Pasqua A et al.
Bmc Medicine, Springer Nature vol. 16 (1) 
13-08-2018

PS-062 Prevalence and explanatory factors for liver function testing and abnormality in a population-based study of children and young people
Li W, Homer K, Boomla K, Robson J, Hull S, Alazawi W
 
01-04-2018

SAT-018 The pathogenic role of Stat2 in inflammation is independent of canonical interferon signaling and is mediated by TNFa
Heath H, Kudo H, Renney G, Ward M, Cutillas P, Goldin RD, Hutchins R, Foster G et al.
 
01-04-2018

FRI-423 Non-invasive liver tests in electronic health records of patients with non-alcoholic fatty liver disease: combined analysis from four European countries
Dhalwani N, Alexander M, Loomis K, Sattar N, Waterworth D, Mosseveld M, Rijnbeek P, van der Lei J et al.
 
01-04-2018

PS-106 Non-alcoholic fatty liver disease and relative risk of incident steatohepatitis, cirrhosis and hepatocellular carcinoma events in four European primary care databases
Alexander M, Loomis K, Dhalwani N, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, Pasqua A et al.
 
01-04-2018

Interfering with Kupffer cell replenishment: New insights into liver injury
Alazawi W, Knolle PA
Journal of Hepatology, Elsevier vol. 68 (4), 635-637.  
17-02-2018

Stat2 Deletion Impairs MAPK Signaling, NF-Kb Localisation to the Nucleus, Cytokine Expression and Is Protective from Sterile Inflammation
Heath H, Britton G, Kudo H, Renney G, Ward M, Goldin RD, Hutchins R, Foster GR et al.
 
01-01-2018

Factors Influencing Global Trends in Liver-Related Mortality - an Observational Study from 1985 to 2015
Li W, Salciccioli JD, Marshall D, Shalhoub J, Alazawi W
 
01-01-2018

Non-Alcoholic Fatty Liver Disease and Risk of Acute Myocardial Infarction and Stroke: Analysis of 18 Million Patients in Four European Primary Care Databases.
Alexander M, Loomis K, Dhalwani N, Van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, Pasqua A et al.
 
01-01-2018

Primary care recorded NAFLD and the risk of incident MI and stroke: Findings from analyses of 18 million patients in the UK, the Netherlands, Spain, and Italy
Alexander M, Loomis KA, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, Lapi F, Rijnbeek P et al.
 
01-01-2018

Body mass index and the risk of cardiovascular disease and all-cause mortality in European primary care databases
Alexander M, Dhalwani NN, Rijnbeek P, Mosseveld M, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D et al.
 
01-01-2018

Periodontitis is associated with significant hepatic fibrosis in patients with non-alcoholic fatty liver disease
Alazawi W, Bernabe E, Tai D, Kemos P, Turner W
Plos One, Public Library of Science (Plos) vol. 12 (12) 
08-12-2017

Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent
De Silva S, Li W, Kemos P, Brindley JH, Mecci J, Samsuddin S, Chin-Aleong J, Feakins RM et al.
Frontline Gastroenterology, Bmj vol. 9 (2) 
16-11-2017

PWE-075 Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of south asian descent
De Silva S, Li W, Kemos P, Brindley J, Mecci J, Samsuddin S, Chin-Aleong J, Feakins R et al.
Liver. 
17-06-2017

OC-080 Stat2 is a key mediator of acute pancreatitis
Heath H, Renney G, Ward M, Cutillas P, Kudu H, Goldin R, Hutchins R, Foster G et al.
Science Masterclass: Signalling in Epithelial Cancer and Inflammation – Gastric. 
17-06-2017

Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey
Sheridan DA, Aithal G, Alazawi W, Allison M, Anstee Q, Cobbold J, Khan S, Fowell A et al.
Frontline Gastroenterology, Bmj vol. 8 (4) 
28-04-2017

Methotrexate Hepatotoxicity and the Impact of Nonalcoholic Fatty Liver Disease
Shetty A, Cho W
The American Journal of The Medical Sciences, Elsevier vol. 354 (2), 172-181.  
14-03-2017

SAT-321 Periodontitis is strongly associated with NAFLD in the NHANES III cohort and in an independent prospective study, is more common in those with biopsy-proven advanced compared to mild liver disease
Alazawi W, Tai DF, Kemos P, Bernabe E, Janicki T, Gillam D, Syn WK
 
01-01-2017

SAT-320 Blood-test based assessment of liver fibrosis, but not transient elastography, is less accurate in NAFLD patients of South Asian compared to White ethnicity
De Silva S, Li W, Kemos P, Brindley JH, Feakins R, Chinaleong J, Samsuddin S, Foster GR et al.
 
01-01-2017

LBP-541 Hepatic fibrosis is associated with histological activity in nonalcoholic steatohepatitis: an analysis from a large database of screening biopsies in the CENTAUR trial
Ratziu V, Wong VW-S, Lanthier N, Boursier J, Alazawi W, Kluwe J, Genesca J, Andreone P et al.
 
01-01-2017

LBP-528 Incidence and prevalence of recorded non-alcoholic fatty liver disease in four large European primary care databases covering 21.9 million adults
Alexander M, Loomis K, Fairburn-Beech J, van der Lei J, Duarte-Salles T, Ansell D, Pasqua A, Rijnbeek P et al.
 
01-01-2017

Inflammatory and Immune Responses to Surgery and Their Clinical Impact
Alazawi W, Pirmadjid N, Lahiri R
Annals of Surgery, Wolters Kluwer vol. 264 (1), 73-80.  
01-07-2016

PWE-144 Predicting Treatment Failure in C.Difficile Infection: A Prospective Observational Cohort Study
Joshi N, Goodhand J, Alazawi W, Wilks M, Rampton D
BSG 2016. 
01-06-2016

Systemic Inflammatory Response Syndrome After Major Abdominal Surgery Predicted by Early Upregulation of TLR4 and TLR5
Lahiri R, Derwa Y, Bashir Z, Giles E, Torrance HDT, Owen HC, O’Dwyer MJ, O’Brien A et al.
Annals of Surgery, Wolters Kluwer vol. 263 (5), 1028-1037.  
01-05-2016

PTH-102 Stat2 is a key inflammatory molecule in human non-alcoholic fatty liver disease and murine liver injury
Alazawi W, Heath H, Petts G, Kudu H, Feakins R, O’Brien A, Goldin R, Foster G
Liver – Basic Science. 
01-06-2015

PTU-117 Sequential NUC therapy following pegylated interferon provides a greater decline in HBSAG and potentially offers a treatment advantage over current therapies
Gill, Hansi N, Payaniandy L, Schulz J, Payaniandy D, Alazawi W, Dearden J, Kallis Y et al.
Liver – Viral Hepatitis. 
01-06-2015

PTH-093 One year mortality outcomes of patients with liver cirrhosis admitted to a teaching hospital intensive care unit
Tai D, Lewis H, Derwa Y, Lillis A, Reynolds T, Maitland K, Hall D, Alazawi W et al.
 
01-06-2015

P0001 : Early monocyte dysfunction in patients who develop Systemic Inflammatory Response Syndrome (SIRS) and sepsis after hepatopancreaticobiliary surgery
Lahiri R, Derwa Y, Bashir Z, Giles E, Torrance H, O’Dwyer M, Owen H, O’Brien A et al.
 
01-04-2015

Practical approach to non‐alcoholic fatty liver disease in patients with diabetes
Tai FWD, Syn W-K
Diabetic Medicine, Wiley vol. 32 (9), 1121-1133.  
18-03-2015

Association Between Early Postoperatively Elevated TLR-4 & TLR-5 Gene Expression and Late Nosocomial Infection in Elective High-Risk Hepato-Pancreato-Biliary (HPB) Surgery
Pirmadjid N, Torrance HDT, Owen HC, Alazawi W
 
01-01-2015

Research into practice: understanding ethnic differences in healthcare usage and outcomes in general practice
Hull S, Mathur R, Boomla K, Chowdhury TA, Dreyer G, Alazawi W, Robson J
British Journal of General Practice, Royal College of General Practitioners vol. 64 (629), 653-655.  
01-12-2014

Ethnicity and the diagnosis gap in liver disease: a population-based study.
Alazawi W, Mathur R, Abeysekera K, Hull S, Boomla K, Robson J, Foster GR
Br J Gen Pract vol. 64 (628), e694-e702.  
01-11-2014

PTU-138 Population-based Study Of Ethnicity And The Diagnosis Gap In Liver Disease.
Alazawi W, Mathur R, Abeysekera K, Hull S, Boomla K, Robson J, Foster G
Gut vol. 63 Suppl 1 
01-06-2014

PWE-142 Is Liver Disease Overlooked In Patients With Psoriasis?
Ooi J, Chinthapalli S, O'Toole E
Gut vol. 63 Suppl 1 
01-06-2014

PTH-080 Risk Profile For Non-alcoholic Fatty Liver Disease (nafld) In A Paediatric Specialist Care Setting.
Tai F, Derwa Y, Naik S
Gut vol. 63 Suppl 1, A244-A245.  
01-06-2014

Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2.
O'Brien AJ, Fullerton JN, Massey KA, Auld G, Sewell G, James S, Winstanley A, Cordoba J et al.
Nat Med vol. 20 (5), 518-523.  
01-05-2014

O154 PROSTAGLANDIN E2 MEDIATES IMMUNOSUPPRESSION IN ACUTELY DECOMPENSATED CIRRHOSIS
O'Brien A, Fullerton J, Auld G, Newson J, Karra E, Alazawi W, Winstanley A, Juan C et al.
 
01-04-2014

Humanized Culture of Periosteal Progenitors in Allogeneic Serum Enhances Osteogenic Differentiation and In Vivo Bone Formation
Roberts SJ, Owen HC, Tam WL, Solie L, Van Cromphaut SJ, Van den Berghe G, Luyten FP
Stem Cells Translational Medicine, Oxford University Press (Oup) vol. 3 (2), 218-228.  
27-12-2013

Maintaining clinical governance when giving telephone advice
Alazawi W, Agarwal K, Aluvihare V
Frontline Gastroenterology, Bmj vol. 4 (4) 
06-07-2013

A cross sectional study of colonic diverticulosis in the London Bangladeshi population.
Lahiri RP, Abeles A, Burnand KM, Alazawi W, Bhattacharya S, Foster GR, Knowles CH
United European Gastroenterol J vol. 1 (3), 191-197.  
01-06-2013

PTH-178 Who Calls the Liver Registrar at King’S?
Alazawi W, Agarwal K, Suddle A, Aluvihare V
 
01-06-2013

OC-041 Enhanced Monocyte Function and Surface TLR Expression Predict Post-Operative Systemic Inflammatory Response Syndrome in Patients Immediately following Major Hepatic and Pancreatic Resection
Lahiri R, Wong J, Bhattacharya S, Foster G
Gut, Bmj vol. 62 (Suppl 1) 
01-06-2013

Stat2 loss leads to cytokine-independent, cell-mediated lethality in LPS-induced sepsis.
Alazawi W, Heath H, Waters JA, Woodfin A, O'Brien AJ, Scarzello AJ, Ma B, Lopez-Otalora Y et al.
Proc Natl Acad Sci U S A vol. 110 (21), 8656-8661.  
21-05-2013

319 PATIENTS WITH COMPENSATED CIRRHOSIS HAVE SELECTIVE PARESIS OF FLAGELLIN-INDUCED INNATE IMMUNE RESPONSES DUE TO FAILURES IN ERK SIGNALLING
Alazawi W, Lahiri R, Spyrou A, Giles E, Bashir Z, O'Brien A, Stagg A, Waters J et al.
 
01-04-2013

The London Bangladeshi community: A population protected against the disease of western civilisation
Lahiri R, Abeles A, Burnand K, Alazawi W, Foster G, Knowles C
 
01-01-2013

Increased expression of toll-like receptor (TLR) 4 and TLR5 following complex hepato-pancreatico-biliary (HPB) surgery predicts the development of post-operative systemic inflammatory response syndrome (SIRS)
Lahiri R, Wong J, Waters J, Bhattacharya S, Foster G, Alazawi W
 
01-01-2013

POPULATION BASED STUDY OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) SHOWS DISEASE IS MORE COMMON AMONG BANGLADESHIS IN ETHNICALLY DIVERSE BOROUGHS OF LONDON
Alazawi W, Abeysekera K, Boomla K, Foster GR
 
01-01-2013

IMPLEMENTING EASL & AASLD GUIDELINES FOR HEPATOCELLULAR CARCINOMA SCREENING IS COST-EFFECTIVE IN LONDON'S ETHNICALLY DIVERSE POPULATION
Alazawi W, Abeysekera K, Dearden J, Glynn M, Kallis Y, Kennedy P, Marley R, Foster GR et al.
 
01-01-2013

RISES IN BOTH WHITE CELL COUNT AND CRP AT DAY 3 PREDICT FAILURE OF TREATMENT WITH METRONIDAZOLE IN C.DIFFICILE INFECTION
Joshi NM, Kok K, Alazawi W, Rampton DS
 
01-01-2013

Endothelin-1 as a mediator and potential biomarker for interferon induced pulmonary toxicity.
George PM, Cunningham ME, Galloway-Phillipps N, Badiger R, Alazawi W, Foster GR, Mitchell JA
Pulm Circ vol. 2 (4), 501-504.  
01-10-2012

Pharmacology and therapeutic potential of interferons.
George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA
Pharmacol Ther vol. 135 (1), 44-53.  
01-07-2012

An orally available, small-molecule interferon inhibits viral replication.
Konishi H, Okamoto K, Ohmori Y, Yoshino H, Ohmori H, Ashihara M, Hirata Y, Ohta A et al.
Sci Rep vol. 2 
01-01-2012

FLAGELLIN-INDUCED IL-6 PRODUCTION IS SELECTIVELY IMPAIRED IN PATIENTS WITH CIRRHOSIS
Alazawi W, Spyrou A, Lahiri R, Waters J, Foster GR
Gut vol. 61, A130-A130.  
01-01-2012

EVALUATION OF LIVER FIBROSIS IN YOUNG ADULT PATIENTS WITH CHRONIC HEPATITIS B VIRUS
Patel C, Gill US, Alazawi W, Shaw P, Alstead E, Kallis Y, Kooner P, Marley R et al.
Gut vol. 61, A133-A133.  
01-01-2012

Stat2 loss is associated with enhanced inflammatory cell egress and hepatitis after LPS stimulation despite abolishing inflammatory cytokine production: a novel model of liver inflammation
Alazawi W, Waters JA, Heath H, Woodfin A, O'Brien A, Jacobs M, Goldin R, Nourshargh S et al.
 
01-01-2012

Benchmarking disease activity and progression in Chronic Hepatitis B infected young adults
Patel C, Gill U, Alazawi W, Shaw P, Alstead EM, Kallis Y, Kooner P, Marley R et al.
 
01-01-2012

P93 NFκB activation by TLR agonists is deficient in macrophages lacking STAT2
Alazawi W, Gamero A, Heath H, Smith P, Jacobs M, Waters J, Foster GR
Gut, Bmj vol. 60 (Suppl 2) 
01-09-2011

Benefits of knowledge-based interprofessional communication skills training in medical undergraduate education.
Buczacki S, Shalhoub J, George PM, Vearncombe LM, Alazawi W
Jrsm Short Rep vol. 2 (8) 
01-08-2011

Efficacy of Combination Tenofovir Plus Lamivudine Versus Tenofovir Monotherapy in Patients With Chronic Hepatitis B Virus
Glyn FJ, Gill U, Alazawi W, Ross V, Kooner P, Marley R, Foster G, Kennedy PT
 
01-05-2011

SYSTEMATIC REVIEW: CLOSTRIDIUM DIFFICILE AND IBD
Goodhand JR, Alazawi W
 
01-04-2011

EFFICACY OF COMBINATION TENOFOVIR PLUS LAMIVUDINE VERSUS TENOFOVIR MONOTHERAPY IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS
Glyn F, Gill US, Alazawi W, Ross V, Kooner P, Marley R, Foster GR, Kennedy PTF
 
01-04-2011

Systematic review: Clostridium difficile and inflammatory bowel disease.
Goodhand JR, Alazawi W
Aliment Pharmacol Ther vol. 33 (4), 428-441.  
01-02-2011

Other Liver Viruses
ALAZAWI W, Lewis H, Foster GR
Medicine, Elsevier vol. 39 (9), 561-563.  
01-01-2011

CAN AN EX VIVO HUMAN LIVER BIOPSY MODEL BE USED TO TEST THE EFFICACY OF DRUGS FOR THE TREATMENT OF HEPATITIS C?
Javaid A, Hibbert L, Waters JA, Alazawi W, Foster GR
 
01-10-2010

Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection.
Alazawi W, Cunningham M, Dearden J, Foster GR
Aliment Pharmacol Ther vol. 32 (3), 344-355.  
01-08-2010

Ready to Excel
Alazawi W
 
24-06-2010

Combination Therapy for Chronic Hepatitis B Virus Infection: Should we use it ab initio or Sequentially?
ALAZAWI W, Foster GR
In Clinical Dilemmas in Viral Liver Disease, Wiley-Blackwell 
10-05-2010

NATURAL HISTORY OF COMPENSATED CIRRHOSIS DUE TO CHRONIC HEPATITIS C INFECTION: A SYSTEMATIC REVIEW
Alazawi W, Cunningham M, Dearden J, Foster GR
 
01-04-2010

Mycobacterium mucogenicum causing central line-related sepsis in a home parenteral nutrition patient
Simpson AI, Alazawi W, Warwick S, Sheridan E
 
01-01-2010

Case 36 Syncope in a Patient with Noonan Syndrome
Alazawi W
In Cases in Adult Congenital Heart Disease, Elsevier 199-204.  
01-01-2010

NATURAL HISTORY OF COMPENSATED CIRRHOSIS DUE TO CHRONIC HEPATITIS C INFECTION: A SYSTEMATIC REVIEW
Alazawi W, Cunningham M, Dearden J, Foster GR
 
01-01-2010

SUBSTITUTION OF ADEFOVIR FOR TENOFOVIR IN PATIENTS WITH CHRONIC HBV RECEIVING COMBINATION THERAPY WHO HAVE INCOMPLETE CONTROL OR VIROLOGICAL BREAKTHROUGH - IS IT WORTH-WHILE?
Alazawi W, Cottle R, Ross V, Ushiro-Lumb I, Alstead EM, Glynn M, Marley R, Foster GR
 
01-10-2009

Syncope in a Patient with Noonan Syndrome
ALAZAWI W
In Cases in Adult Congenital Heart Disease, Churchill Livingstone 
10-07-2009

STAT2 IS A MAJOR DETERMINANT OF HEPATIC INFLAMMATION AND MORTALITY IN A KNOCKOUT MOUSE MODEL OF PERITONEAL INFLAMMATION
Alazawi W, Gamero A, Waters J, Jacobs M, Foster G
 
01-01-2009

Advances in the diagnosis and treatment of hepatitis B.
Alazawi W, Foster GR
Curr Opin Infect Dis vol. 21 (5), 508-515.  
01-10-2008

Interferon-β treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants
Herdman MT, Pett MR, Roberts I, Alazawi WOF, Teschendorff AE
Carcinogenesis vol. 27 (11), 2341-2353.  
01-01-2006

Genomic imbalances in 70 snap-frozen cervical squamous intraepithelial lesions: associations with lesion grade, state of the HPV16 E2 gene and clinical outcome.
Alazawi W, Pett M, Strauss S, Moseley R, Gray J, Coleman N
Br J Cancer vol. 91 (12), 2063-2070.  
13-12-2004

In vitro acid exposure has a differential effect on apoptotic and proliferative pathways in a Barrett's adenocarcinoma cell line.
Morgan C, Alazawi W, Sirieix P, Freeman T
Am J Gastroenterol vol. 99 (2), 218-224.  
01-02-2004

Acquisition of High-Level Chromosomal Instability Is Associated with Integration of Human Papillomavirus Type 16 in Cervical Keratinocytes
Pett MR, ALAZAWI W, Roberts I, Dowen S, Smith DI, Coleman N
Cancer Research, American Association For Cancer Research vol. 64 (4), 1359-1368.  
01-01-2004

Primary or secondary malignancy? Fingerprint evidence.
Alazawi W, Gonzalez M, Arends M, Coleman N
Clin Oncol (R Coll Radiol) vol. 15 (7), 408-411.  
01-10-2003

Acquisition of high-level genomic instability is associated with integration of HPV16 in cervical keratinocytes
Pett MR, Alazawi W, Roberts I, Stanley MA
 
01-09-2003

Immediate and early gene response to in vitro acid exposure in a Barrett's adenocarcinoma cell line
Morgan C, Alazawi W, Coleman N, Fitzgerald R
 
01-04-2003

Altered expression of desmosomal components in high-grade squamous intraepithelial lesions of the cervix
ALAZAWI W, Morris LS, Garrod DR
Virchows Archiv: The European Journal of Pathology, Springer vol. 443 (1), 51-56.  
01-01-2003

Changes in cervical keratinocyte gene expression associated with integration of human papillomavirus 16.
Alazawi W, Pett M, Arch B, Scott L, Freeman T, Stanley MA
Cancer Res vol. 62 (23), 6959-6965.  
01-12-2002

Changes in host cell genome and transcriptome associated with integration of HPV 16 in cervical keratinocytes
Alazawi W, Pett M, Stanley M, Coleman N
J Pathol vol. 198, 8A-8A.  
01-09-2002

Mapping vascular plasticity in liver fibrogenesis identifies novel fibrosis-associated endothelial cells in early-stage liver disease
Gkantsinikoudi C, Dignam JP, Kumar R, Jokl E, Li W, Samus M, Landi S, Athwal VS et al.
In Biorxiv 

adam17
Alazawi W
Frontiers in Immunology, Frontiers Media 

Stat2 loss disrupts damage signalling and is protective in acute pancreatitis
Heath H, Britton G, Kudo H, Renney G, Ward M, Hutchins R, Foster GR, Goldin R et al.
In Biorxiv